Response and Resistance to ER-Directed Therapy in Metastatic Breast Cancer

Request Access

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.

R. Jeselsohn, R. Jeselsohn, J. Bergholz, et al.. (2018). Cancer cell. Cited 226 times. https://doi.org/10.1016/j.ccell.2018.01.004

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

U. Nayar, Ofir Cohen, Christian Kapstad, et al.. (2018). Nature Genetics. Cited 202 times. https://doi.org/10.1038/s41588-018-0287-5

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer.

Seth A. Wander, Ofir Cohen, Xueqian Gong, et al.. (2020). Cancer discovery. Cited 122 times. https://doi.org/10.1158/2159-8290.CD-19-1390

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

Pingping Mao, Ofir Cohen, Kailey J. Kowalski, et al.. (2019). Clinical Cancer Research. Cited 108 times. https://doi.org/10.1158/1078-0432.CCR-19-3958

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial

Jorge Gómez Tejeda Zañudo, R. Barroso-Sousa, Esha Jain, et al.. (2024). Nature Communications. Cited 18 times. https://doi.org/10.1038/s41467-024-45835-6
NCPI Dataset Catalog
Feedback & Support
v0.9.0-d9e5747